Chemical structure and tumor type specificity of 'half-mustard type' phenothiazines

Noboru Motohashi, Teruo Kurihara, Hiroshi Sakagami, Diana Szabo, Klara Csuri, J. Molnár

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

The antiproliferative activity of six 'half-mustard type' phenothiazines against a total of 54 tumor cell lines: 4 leukemia, 9 non-small-cell lung, 7 colon-, 5 CNS-, 8 melanoma, 6 ovarian-, 8 renal-, 1 prostate and 6 breast cancer was determined by NCI-Information Intensive-Approach. The C-2 position of phenothiazines were substitutes with H, Cl and CF3 groups. The half-mustard and ring system was linked either by a propylene or a butylene bridge. Colon-cancer cell showed the highest sensitivity against 'half-mustard type' phenothiazines, followed by leukemia, melanoma, prostate-, CNS-, breast-, lung-, renal and ovarian cancer cells. These data suggest the 'cancer-type-specific' antitumor action of 'half-mustard type' phenothiazines.

Original languageEnglish
Pages (from-to)1859-1864
Number of pages6
JournalAnticancer Research
Volume19
Issue number3 A
Publication statusPublished - 1999

Fingerprint

Phenothiazines
Mustard Plant
Prostate
Melanoma
Neoplasms
Leukemia
Breast Neoplasms
Kidney Neoplasms
Tumor Cell Line
Ovarian Neoplasms
Colonic Neoplasms
Lung Neoplasms
Colon
Kidney
Lung

Keywords

  • 'Half-mustard type' phenothiazines
  • Antitumor activity
  • Specificity
  • Structure

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Motohashi, N., Kurihara, T., Sakagami, H., Szabo, D., Csuri, K., & Molnár, J. (1999). Chemical structure and tumor type specificity of 'half-mustard type' phenothiazines. Anticancer Research, 19(3 A), 1859-1864.

Chemical structure and tumor type specificity of 'half-mustard type' phenothiazines. / Motohashi, Noboru; Kurihara, Teruo; Sakagami, Hiroshi; Szabo, Diana; Csuri, Klara; Molnár, J.

In: Anticancer Research, Vol. 19, No. 3 A, 1999, p. 1859-1864.

Research output: Contribution to journalArticle

Motohashi, N, Kurihara, T, Sakagami, H, Szabo, D, Csuri, K & Molnár, J 1999, 'Chemical structure and tumor type specificity of 'half-mustard type' phenothiazines', Anticancer Research, vol. 19, no. 3 A, pp. 1859-1864.
Motohashi N, Kurihara T, Sakagami H, Szabo D, Csuri K, Molnár J. Chemical structure and tumor type specificity of 'half-mustard type' phenothiazines. Anticancer Research. 1999;19(3 A):1859-1864.
Motohashi, Noboru ; Kurihara, Teruo ; Sakagami, Hiroshi ; Szabo, Diana ; Csuri, Klara ; Molnár, J. / Chemical structure and tumor type specificity of 'half-mustard type' phenothiazines. In: Anticancer Research. 1999 ; Vol. 19, No. 3 A. pp. 1859-1864.
@article{bcdc124a30774f97809922bff41af99f,
title = "Chemical structure and tumor type specificity of 'half-mustard type' phenothiazines",
abstract = "The antiproliferative activity of six 'half-mustard type' phenothiazines against a total of 54 tumor cell lines: 4 leukemia, 9 non-small-cell lung, 7 colon-, 5 CNS-, 8 melanoma, 6 ovarian-, 8 renal-, 1 prostate and 6 breast cancer was determined by NCI-Information Intensive-Approach. The C-2 position of phenothiazines were substitutes with H, Cl and CF3 groups. The half-mustard and ring system was linked either by a propylene or a butylene bridge. Colon-cancer cell showed the highest sensitivity against 'half-mustard type' phenothiazines, followed by leukemia, melanoma, prostate-, CNS-, breast-, lung-, renal and ovarian cancer cells. These data suggest the 'cancer-type-specific' antitumor action of 'half-mustard type' phenothiazines.",
keywords = "'Half-mustard type' phenothiazines, Antitumor activity, Specificity, Structure",
author = "Noboru Motohashi and Teruo Kurihara and Hiroshi Sakagami and Diana Szabo and Klara Csuri and J. Moln{\'a}r",
year = "1999",
language = "English",
volume = "19",
pages = "1859--1864",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3 A",

}

TY - JOUR

T1 - Chemical structure and tumor type specificity of 'half-mustard type' phenothiazines

AU - Motohashi, Noboru

AU - Kurihara, Teruo

AU - Sakagami, Hiroshi

AU - Szabo, Diana

AU - Csuri, Klara

AU - Molnár, J.

PY - 1999

Y1 - 1999

N2 - The antiproliferative activity of six 'half-mustard type' phenothiazines against a total of 54 tumor cell lines: 4 leukemia, 9 non-small-cell lung, 7 colon-, 5 CNS-, 8 melanoma, 6 ovarian-, 8 renal-, 1 prostate and 6 breast cancer was determined by NCI-Information Intensive-Approach. The C-2 position of phenothiazines were substitutes with H, Cl and CF3 groups. The half-mustard and ring system was linked either by a propylene or a butylene bridge. Colon-cancer cell showed the highest sensitivity against 'half-mustard type' phenothiazines, followed by leukemia, melanoma, prostate-, CNS-, breast-, lung-, renal and ovarian cancer cells. These data suggest the 'cancer-type-specific' antitumor action of 'half-mustard type' phenothiazines.

AB - The antiproliferative activity of six 'half-mustard type' phenothiazines against a total of 54 tumor cell lines: 4 leukemia, 9 non-small-cell lung, 7 colon-, 5 CNS-, 8 melanoma, 6 ovarian-, 8 renal-, 1 prostate and 6 breast cancer was determined by NCI-Information Intensive-Approach. The C-2 position of phenothiazines were substitutes with H, Cl and CF3 groups. The half-mustard and ring system was linked either by a propylene or a butylene bridge. Colon-cancer cell showed the highest sensitivity against 'half-mustard type' phenothiazines, followed by leukemia, melanoma, prostate-, CNS-, breast-, lung-, renal and ovarian cancer cells. These data suggest the 'cancer-type-specific' antitumor action of 'half-mustard type' phenothiazines.

KW - 'Half-mustard type' phenothiazines

KW - Antitumor activity

KW - Specificity

KW - Structure

UR - http://www.scopus.com/inward/record.url?scp=0032774025&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032774025&partnerID=8YFLogxK

M3 - Article

C2 - 10470128

AN - SCOPUS:0032774025

VL - 19

SP - 1859

EP - 1864

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3 A

ER -